Vertex Pharmaceuticals Inc

VRTX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
VRTX Income Statement
VRTX Balance Sheet
VRTX Cash Flow
Congress Trading

Recent trades of VRTX by members of U.S. Congress

Politician Type Traded
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 May. 03, 2024
HON. GREG STANTON House / D Sale $1,001 - $15,000 Oct. 24, 2023
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 Oct. 06, 2022
William R. Keating House / D Purchase $1,001 - $15,000 Mar. 29, 2022
Peter Meijer House / R Sale $1,001 - $15,000 Jan. 28, 2021
Dean Phillips House / D Purchase $1,001 - $15,000 Dec. 18, 2020
Josh Gottheimer House / D Sale $1,001 - $15,000 Sep. 19, 2019
Donna E. Shalala House / D Sale $1,001 - $15,000 Jun. 24, 2019
Donna E. Shalala House / D Purchase $1,001 - $15,000 Apr. 18, 2019
Josh Gottheimer House / D Sale $1,001 - $15,000 Apr. 11, 2019
Gilbert Ray Cisneros, Jr. House / D Sale $15,001 - $50,000 Feb. 27, 2019
Gilbert Ray Cisneros, Jr. House / D Sale $15,001 - $50,000 Feb. 26, 2019
Jack Reed Senate / D Sale (Full) $1,001 - $15,000 Feb. 04, 2019
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Jan. 31, 2019
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun. 01, 2018
Josh Gottheimer House / D Sale $1,001 - $15,000 May. 01, 2018
Jack Reed Senate / D Sale (Partial) $1,001 - $15,000 Mar. 09, 2018
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jul. 19, 2017
Josh Gottheimer House / D Purchase $1,001 - $15,000 Apr. 13, 2017
Thomas MacArthur House / R Purchase $1,001 - $15,000 Nov. 02, 2016
Thomas MacArthur House / R Purchase $1,001 - $15,000 Nov. 01, 2016
K. Michael Conaway House / R Sale $1,001 - $15,000 Sep. 12, 2016
Thomas MacArthur House / R Sale $1,001 - $15,000 Feb. 02, 2016
Jack Reed Senate / D Sale (Partial) $1,001 - $15,000 May. 13, 2015
VRTX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
VRTX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
VRTX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by VRTX's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $1,000,000 Oct 18, 2024 Issue: Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $980,000 Jul 15, 2024 Issue: Medicare/Medicaid Health Issues
  • $1,150,000 Apr 18, 2024 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues
  • $60,000 Jan 22, 2024 Issue: Health Issues Medicare/Medicaid
  • $50,000 Jan 22, 2024 Issue: Health Issues
  • $30,000 Jan 20, 2024 Issue: Budget/Appropriations Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
  • $80,000 Jan 12, 2024 Issue: Health Issues Medicare/Medicaid
  • $890,000 Oct 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
  • $630,000 Jul 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
  • $670,000 Apr 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
  • $370,000 Jan 18, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Health Issues
  • $710,000 Oct 14, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Health Issues
  • $520,000 Jul 19, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $520,000 Apr 20, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $630,000 Jan 20, 2022 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $450,000 Oct 20, 2021 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Medicare/Medicaid
  • $420,000 Jul 19, 2021 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $570,000 May 21, 2021 Issue: Health Issues Medicare/Medicaid
  • $410,000 Apr 19, 2021 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $380,000 Oct 20, 2020 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $380,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $390,000 Apr 20, 2020 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $530,000 Jan 21, 2020 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $310,000 Oct 21, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $310,000 Jul 22, 2019 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $320,000 Apr 19, 2019 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $450,000 Jan 21, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $340,000 Oct 19, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $350,000 Jul 18, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $350,000 Apr 19, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $340,000 Jan 19, 2018 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues
  • $340,000 Oct 19, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $560,000 Jul 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $450,000 Apr 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $340,000 Jan 20, 2017 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues
  • $350,000 Oct 20, 2016 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $440,000 Jul 20, 2016 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $210,000 Apr 20, 2016 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $350,000 Jan 19, 2016 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark
  • $330,000 Oct 20, 2015 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $300,000 Jul 20, 2015 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
  • $380,000 Apr 20, 2015 Issue: Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Medicare/Medicaid
  • $210,000 Jan 19, 2015 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $280,000 Oct 16, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $480,000 Jul 21, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
  • $190,000 Apr 21, 2014 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues
  • $210,000 Jan 20, 2014 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
  • $210,000 Oct 21, 2013 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $460,000 Jul 18, 2013 Issue: Health Issues
  • $300,000 Apr 22, 2013 Issue: Health Issues
  • $260,000 Jan 22, 2013 Issue: Budget/Appropriations Health Issues
  • $250,000 Oct 19, 2012 Issue: Health Issues Budget/Appropriations
  • $360,000 Jul 20, 2012 Issue: Budget/Appropriations Health Issues
  • $490,000 Apr 20, 2012 Issue: Health Issues Budget/Appropriations
  • $480,000 Jan 19, 2012 Issue: Health Issues Budget/Appropriations
  • $360,000 Oct 20, 2011 Issue: Health Issues Budget/Appropriations
  • $450,000 Jul 19, 2011 Issue: Health Issues
  • $460,000 Apr 20, 2011 Issue: Health Issues
  • $140,000 Jan 19, 2011 Issue: Health Issues
  • $370,000 Oct 20, 2010 Issue: Health Issues
  • $170,000 Jul 20, 2010 Issue: Health Issues
  • $300,000 Apr 20, 2010 Issue: Health Issues
  • $120,000 Jan 20, 2010 Issue: Health Issues
  • $130,000 Oct 20, 2009 Issue: Health Issues
  • $130,000 Jul 20, 2009 Issue: Health Issues
  • $180,000 Apr 20, 2009 Issue: Health Issues
  • $100,000 Jan 21, 2009 Issue: Health Issues
  • $120,000 Oct 20, 2008 Issue: Health Issues
  • $80,000 Jul 21, 2008 Issue: Health Issues
  • $80,000 Apr 21, 2008 Issue: Science/Technology Medical/Disease Research/Clinical Labs Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Materials and methods for treatment of hemoglobinopathies Nov. 05, 2024
  • Patent Title: Materials and methods for treatment of human genetic diseases including hemoglobinopathies Oct. 29, 2024
  • Patent Title: Process of making cftr modulators Oct. 22, 2024
  • Patent Title: Dna-pk inhibitors Oct. 22, 2024
  • Patent Title: Complement factor i-related compositions and methods Oct. 15, 2024
  • Patent Title: Inhibitors of apol1 and methods of using same Oct. 15, 2024
  • Patent Title: Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid Aug. 20, 2024
  • Patent Title: Inhibitors of apol1 and methods of using same Aug. 13, 2024
  • Patent Title: Materials and methods for treatment of duchenne muscular dystrophy Aug. 06, 2024
  • Patent Title: Materials and methods for treatment of hemoglobinopathies Jul. 23, 2024
  • Patent Title: Methods, compositions and kits for increasing genome editing efficiency Jul. 09, 2024
  • Patent Title: Processes for making modulators of cystic fibrosis transmembrane conductance regulator Jul. 02, 2024
  • Patent Title: Differentiation of pancreatic endocrine cells Jun. 11, 2024
  • Patent Title: Dna-pk inhibitors Jun. 11, 2024
  • Patent Title: Stem cell derived islet differentiation Jun. 04, 2024
  • Patent Title: Stem cell derived pancreatic islet differentiation May. 28, 2024
  • Patent Title: Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors May. 14, 2024
  • Patent Title: Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases Apr. 09, 2024
  • Patent Title: Cell housing device Apr. 09, 2024
  • Patent Title: Islet cell manufacturing compositions and methods of use Apr. 02, 2024
  • Patent Title: Substituted tetrahydrofurans as modulators of sodium channels Mar. 05, 2024
  • Patent Title: Modulators of alpha-1 antitrypsin Jan. 30, 2024
  • Patent Title: Crystalline forms of cftr modulators Jan. 16, 2024
  • Patent Title: Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators Jan. 09, 2024
  • Patent Title: Inhibitors of apol1 and methods of using same Jan. 09, 2024
  • Patent Title: Substituted tetrahydrofurans as modulators of sodium channels Dec. 05, 2023
  • Patent Title: N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels Nov. 28, 2023
  • Patent Title: Dna-pk inhibitors Nov. 14, 2023
  • Patent Title: Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use Nov. 07, 2023
  • Patent Title: Methods of treating apol-1 dependent focal segmental glomerulosclerosis Oct. 31, 2023
  • Patent Title: Prodrugs of pyridone amides useful as modulators of sodium channels Oct. 03, 2023
  • Patent Title: Pharmaceutical composition and administrations thereof Sep. 12, 2023
  • Patent Title: Processes for making modulators of cystic fibrosis transmembrane conductance regulator Jul. 25, 2023
  • Patent Title: Pyridone amides as modulators of sodium channels Jun. 13, 2023
  • Patent Title: Modulators of atp-binding cassette transporters May. 02, 2023
  • Patent Title: Mannose derivatives for treating bacterial infections Apr. 25, 2023
  • Patent Title: Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto Apr. 25, 2023
  • Patent Title: Modulators of alpha-1 antitrypsin Apr. 11, 2023
  • Patent Title: Inhibitors of apol1 and methods of using same Apr. 04, 2023
  • Patent Title: Modified urokinase-type plasminogen activator polypeptides and methods of use Mar. 28, 2023
  • Patent Title: Carboxamides as modulators of sodium channels Mar. 14, 2023
  • Patent Title: Modulators of cystic fibrosis transmembrane conductance regulator Feb. 28, 2023
  • Patent Title: Process of making cftr modulators Feb. 21, 2023
  • Patent Title: Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide Feb. 14, 2023
  • Patent Title: Pteridinone compounds and uses thereof Feb. 07, 2023
  • Patent Title: Materials and methods for treatment of hemoglobinopathies Jan. 31, 2023
  • Patent Title: Pharmaceutical composition and administrations thereof Jan. 31, 2023
  • Patent Title: Method of treating pain Dec. 20, 2022
  • Patent Title: Pharmaceutical composition and administrations thereof May. 12, 2020
  • Patent Title: Methods of preparing inhibitors of influenza viruses replication May. 05, 2020
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of VRTX in WallStreetBets Daily Discussion

VRTX News

Recent insights relating to VRTX

CNBC Recommendations

Recent picks made for VRTX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in VRTX

VRTX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view VRTX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top